11 jan: Indre værdi af SmallCap Danmark A/S er opgjort til 84,0 kr. pr. a..
11 jan: Danish Crown køber tysk slagteri
11-01-2017 07:59:53

Interim report Q1 - 1 September 2016 - 30 November 2016

Relateret indhold
01 dec - 
Chr. Hansen-topchef tildeles og sælger aktier til flere..
29 nov - 
Aktier/åbning: Pandora og Mærsk trækker C20 Cap videre ..
29 nov - 
Aktier/tendens: Banker og forsikringsselskaber under lu..
Relateret debat
28 nov - 
Jeg finder det trods alt meget stabilt at den holder si..
28 nov - 
Næhh Bruellos. De skal have  ny direkt&oslas..
28 nov - 
Måske lige vente til røgen har lagt sig, o..

Hoersholm, 2017-01-11 07:59 CET (GLOBE NEWSWIRE) --

 

Strong organic revenue growth of 11% in Q1 2016/17: Food Cultures & Enzymes (10%), Health & Nutrition (8%) and Natural Colors (13%). EBIT before special items increased by 21% to EUR 66 million.

 

EUR million

Q1

2016/17

Q1

2015/16

Growth

 

 

 

 

Revenue

  241.7

  214.4

13%

EBIT before special items

 65.5

54.0

21%

Profit for the period

47.0

 38.9

21%

Free cash flow before acquisitions, divestments and special items

  (19.1)

  (16.6)

(15)%

 

 

 

 

Organic growth, %

11%

14%

 

Gross margin, %

53.4%

52.3%

 

EBIT margin before special items, %

27.1%

25.2%

 

ROIC excl. goodwill, %

34.3%

33.1%

 

 

“The results in Q1 gave us a good start to the year, and we maintain our guidance for the full year. Both Food Cultures & Enzymes and Natural Colors delivered strong organic growth and improved profitability. The organic growth in Health & Nutrition was still below our long-term ambitions, however, better than expected for the quarter, mainly due to timing of orders. The EBIT margin for the business area was down, partly due to an unfavorable product mix,” says CEO Cees de Jong.

“We made good progress on our focus areas for 2016/17. Our bioprotective cultures continue to deliver strong growth. In Q1, growth was approximately 25%, and the segment now accounts for approximately 5% of the revenue in Food Cultures & Enzymes. In November, we concluded the acquisition of LGG®, and we have initiated integrating the business into Chr. Hansen. The integration of NPC is being concluded and we are starting to reap the synergies from the acquisition. Plant health supported the growth in Health & Nutrition with sales of both Nemix® C and VGR™, and we are making progress in our work to introduce new products in the coming years. Natural Colors showed good progress in Q1.”

 

OUTLOOK FOR 2016/17                                                                   

The outlook for 2016/17 is unchanged compared to the announcement of 26 October 2016.

Organic revenue growth: 8-10% (previously 8-10%)

EBIT margin before special items: slightly increasing (previously slightly increasing)

Free cash flow before acquisitions, divestments and special items:

around EUR 175 million (previously around EUR 175 million)

 

This unaudited interim report has been prepared in accordance with IAS 34 and additional Danish regulations. The interim report has been prepared in accordance with the accounting policies set out in the Annual Report for 2015/16.

 

For further information, please contact:

Cees de Jong, CEO

Tel: +45 4574 7474

Søren Westh Lonning, CFO

Tel: +45 4574 7474

Anders Mohr Christensen, Senior Director, Investor Relations

Tel: +45 4574 7618

 

Forward-looking statements

This announcement contains forward-looking statements. Such statements are subject to risks and uncertainties, as various factors, many of which are beyond the control of Chr. Hansen Holding A/S, may cause actual developments and results to differ materially from the expectations expressed in this announcement.

 

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2015/16 financial year was EUR 949 million. The company has more than 2,700 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen A/S. For further information, please visit www.chr-hansen.com.

Vedhæftet fil: Company announcement Q1.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Genmab/IR: Royalties vil som minimum dække omkostningerne næste år

12-12-2017 14:04:43
Genmabs royaltyindtægter fra salget af selskabets kræftmidler vil i 2018 som minimum dække omkostningerne.Det præciserer Genmabs IR- og kommunikationsdirektør, Rachel Curtis Gravesen, i en e-mail over for Ritzau Finans, efter at selskabet i nattens løb er kommet med en foreløbig prognose for 2018, som angiveligt har givet anledning til en del tolkning i analytikerkredse vedrørende salget af Genmab..

Aktier/middag: Genmab ryger ned på usikkerhed om 2018-forventninger

12-12-2017 11:39:38
Genmab er under hårdt pres på det danske aktiemarked tirsdag, da flere investorer har tolket negativt på ledelsens udmeldinger om 2018 og nu regner med et lavere salg af kræftmidlet Darzalex end tidligere.Aktien dykker 7,7 pct. til 1093 kr. - det største fald i små to år - og nedturen for biotekaktien er med til at tynge C20 Cap-indekset, som dykker 0,3 pct. til 1125,54.Genmab afholdt natten til t..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab/Jefferies: Svært at se væsentlig konkurrencerisiko
2
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen
3
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen - NY
4
Genmab/IR: Royalties vil som minimum dække omkostningerne næste år
5
Novo-rival for godkendt kopiprodukt

Relaterede aktiekurser

Chr Hansen Holding A/S 553,00 0,1% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
12. december 2017 19:00:40
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB3 - 2017-12-12 19:00:40 - 2017-12-12 19:00:40 - 1 - Website: OKAY